“Unless we can find ways of reducing antioxidant levels, late-stage cancer 10 years from now will be as incurable as it is today.”
James D. Watson,
Nobel Laureate,
Director of Human Genome project
ARJUNA Therapeutics has developed Ag5: The first cancer-mitochondrial-specific antioxidant degrader. A unique small molecule to prolong the lifespan of patients with clinical stage cancer and redefine standard of care across solid tumours.
Therapeutic Molecular Clusters takes a new approach to cancer treatments. Our lead drug acts as a catalyst and we are targeting a known Achilles heel for multiple cancer indications.
Therapeutic Molecular Clusters (TMC's) are a new class of medicine that act as catalysts within the cell structure. We influence a reaction without being permanently altered or consumed by the process.
Arjuna biotech medical research and development. As any person with cancer knows, a diagnosis of cancer also affects every family member and a broader network of relationships. Our vision is to remove the fear of a cancer diagnosis for every patient and every family.
Sign up to hear from us.
Please send us a message, sign up for our newsletter at info@arjunatherapeutics.com
7Polig. Ind. Novo Milladoiro C/ Xesta, nº 78A. 15895 Milladoiro, A Coruña | Spain
Monday - Friday: 8:00am - 5:00pm
Saturday - Sunday: Closed
Arjuna Therapeutics does not make any representation or warranty, express or implied, as to the accuracy or completeness of the information contained herein and therein shall not have any liability for such information. Neither this website nor any link in this website to other information constitutes an offer or invitation for the sale or purchase of securities. The information set out herein and therein is preliminary and should not be relied upon for any purpose.
Copyright © 2021 Arjuna Therapeutics - All Rights Reserved.
"Very Small Molecules, Very Big Impact!"